000			nab a22 7a 4500
999			_c16850 _d16850
003			PC16850
005			20220513131048.0
008			220513b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_93039 _aMuñoz Gallego, Irene _eMicrobiología y Parasitología
100			_93040 _aInfiesta Madurga, Lucía _eMicrobiología y Parasitología
100			_91616 _aViedma Moreno, Esther _eInstituto de Investigación i+12
100			_93041 _aPérez Montarelo, Dafne _eInstituto de Investigación imas12
100			_978 _aChaves Sánchez, Fernando _eMicrobiología y Parasitología
245	0	0	_aChlorhexidine and mupirocin susceptibilities in methicillin-resistant Staphylococcus aureus isolates from bacteraemia and nasal colonisation. _h[comunicación]
260			_bJournal of global antimicrobial resistance, _c2016
300			_a4:65-69.
500			_aFormato Vancouver: Muñoz Gallego I, Infiesta L, Viedma E, Pérez Montarelo D, Chaves F. Chlorhexidine and mupirocin susceptibilities in methicillin-resistant Staphylococcus aureus isolates from bacteraemia and nasal colonisation. J Glob Antimicrob Resist. 2016 Mar;4:65-69.
501			_aPMID: 27436397
504			_aContiene 22 referencias
520			_aChlorhexidine and mupirocin have been increasingly used in healthcare facilities to eradicate methicillin-resistant Staphylococcus aureus (MRSA) carriage. The aim of this study was to determine the prevalence and mechanisms of chlorhexidine and mupirocin resistance in MRSA from invasive infections and colonisation. MRSA isolates obtained from blood and nasal samples between 2012 and 2014 were analysed. Susceptibility to mupirocin was determined by disk diffusion and Etest and susceptibility to chlorhexidine by broth microdilution. The presence of mupA and qac (A/B and C) genes was investigated by PCR. Molecular typing was performed in high-level mupirocin-resistant (HLMR) isolates. Mupirocin resistance was identified in 15.6% of blood isolates (10.9% HLMR) and 15.1% of nasal isolates (12.0% HLMR). Presence of the mupA gene was confirmed in all HLMR isolates. For blood isolates, chlorhexidine minimum inhibitory concentrations (MICs) ranged from ≤0.125 to 4mg/L and minimum bactericidal concentrations (MBCs) from ≤0.125 to 8mg/L. In nasal isolates, chlorhexidine MICs and MBCs ranged from ≤0.125 to 2mg/L. The qacA/B gene was detected in 2.2% of MRSA isolates (chlorhexidine MIC range 0.25-2mg/L) and the qacC gene in 8.2% (chlorhexidine MIC range ≤0.125-1mg/L). The prevalence of qacC was 18.9% in HLMR isolates and 3.6% in mupirocin-susceptible isolates (P=0.009). Most of the HLMR isolates (97.1%) belonged to ST125 clone. These results suggest that chlorhexidine has a higher potential to prevent infections caused by MRSA. In contrast, mupirocin treatment should be used cautiously to avoid the spread of HLMR MRSA.
710			_981 _aServicio de Microbiología y Parasitología
710			_9625 _aInstituto de Investigación imas12
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc16850.pdf _ySolicitar documento
942			_2ddc _cCOM _n0